Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prime and pull of T cell responses against cancer-exogenous antigens is effective against CPI-resistant tumors.
Troise F, Leoni G, Sasso E, Del Sorbo M, Esposito M, Romano G, Allocca S, Froechlich G, Cotugno G, Capone S, Folgori A, Scarselli E, D'Alise AM, Nicosia A. Troise F, et al. Among authors: d alise am. Mol Ther Oncol. 2024 Jan 10;32(1):200760. doi: 10.1016/j.omton.2024.200760. eCollection 2024 Mar 21. Mol Ther Oncol. 2024. PMID: 38596303 Free PMC article.
Development of a Potency Assay for Nous-209, a Multivalent Neoantigens-Based Genetic Cancer Vaccine.
Bartolomeo R, Troise F, Allocca S, Sdruscia G, Vitale R, Bignone V, Petrone AM, Romano G, D'Alise AM, Ruzza V, Garzia I, Leoni G, Merone R, Lanzaro F, Colloca S, Siani L, Scarselli E, Cotugno G. Bartolomeo R, et al. Among authors: d alise am. Vaccines (Basel). 2024 Mar 19;12(3):325. doi: 10.3390/vaccines12030325. Vaccines (Basel). 2024. PMID: 38543959 Free PMC article.
Phase I trial of viral vector based personalized vaccination elicits robust neoantigen specific antitumor T cell responses.
D'Alise AM, Leoni G, Cotugno G, Siani L, Vitale R, Ruzza V, Garzia I, Antonucci L, Micarelli E, Venafra V, Gogov S, Capone A, Runswick S, Martin-Liberal J, Calvo E, Moreno V, Symeonides SN, Scarselli E, Bechter O. D'Alise AM, et al. Clin Cancer Res. 2024 Mar 20. doi: 10.1158/1078-0432.CCR-23-3940. Online ahead of print. Clin Cancer Res. 2024. PMID: 38506710
Tumor Burden Dictates the Neoantigen Features Required to Generate an Effective Cancer Vaccine.
Garzia I, Nocchi L, Avalle L, Troise F, Leoni G, Seclì L, Antonucci L, Cotugno G, Allocca S, Romano G, Conti L, Caiazza C, Mallardo M, Poli V, Scarselli E, D'Alise AM. Garzia I, et al. Among authors: d alise am. Cancer Immunol Res. 2024 Apr 2;12(4):440-452. doi: 10.1158/2326-6066.CIR-23-0609. Cancer Immunol Res. 2024. PMID: 38331413 Free PMC article.
Vector Aided Microenvironment programming (VAMP): reprogramming the TME with MVA virus expressing IL-12 for effective antitumor activity.
Seclì L, Infante L, Nocchi L, De Lucia M, Cotugno G, Leoni G, Micarelli E, Garzia I, Avalle L, Sdruscia G, Troise F, Allocca S, Romano G, Scarselli E, D'Alise AM. Seclì L, et al. Among authors: d alise am. J Immunother Cancer. 2023 Apr;11(4):e006718. doi: 10.1136/jitc-2023-006718. J Immunother Cancer. 2023. PMID: 37117006 Free PMC article.
Adenoviral-based vaccine promotes neoantigen-specific CD8+ T cell stemness and tumor rejection.
D'Alise AM, Brasu N, De Intinis C, Leoni G, Russo V, Langone F, Baev D, Micarelli E, Petiti L, Picelli S, Fakih M, Le DT, Overman MJ, Shields AF, Pedersen KS, Shah MA, Mukherjee S, Faivre T, Delaite P, Scarselli E, Pace L. D'Alise AM, et al. Sci Transl Med. 2022 Aug 10;14(657):eabo7604. doi: 10.1126/scitranslmed.abo7604. Epub 2022 Aug 10. Sci Transl Med. 2022. PMID: 35947675 Free PMC article.
36 results